CO2024001826A2 - Composiciones estabilizadas de radionucleidos y sus usos - Google Patents
Composiciones estabilizadas de radionucleidos y sus usosInfo
- Publication number
- CO2024001826A2 CO2024001826A2 CONC2024/0001826A CO2024001826A CO2024001826A2 CO 2024001826 A2 CO2024001826 A2 CO 2024001826A2 CO 2024001826 A CO2024001826 A CO 2024001826A CO 2024001826 A2 CO2024001826 A2 CO 2024001826A2
- Authority
- CO
- Colombia
- Prior art keywords
- radiopharmaceutical compositions
- targeting ligand
- stabilized
- compositions
- stabilizer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 239000012217 radiopharmaceutical Substances 0.000 abstract 4
- 229940121896 radiopharmaceutical Drugs 0.000 abstract 4
- 230000002799 radiopharmaceutical effect Effects 0.000 abstract 4
- 239000003381 stabilizer Substances 0.000 abstract 4
- 239000003446 ligand Substances 0.000 abstract 3
- 230000008685 targeting Effects 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000002738 chelating agent Substances 0.000 abstract 2
- 239000002184 metal Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000008365 aqueous carrier Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 238000003608 radiolysis reaction Methods 0.000 abstract 1
- -1 small molecule compound Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
En el presente documento, se proporcionan composiciones radiofarmacéuticas y sus usos. Las composiciones radiofarmacéuticas pueden comprender uno o más agentes estabilizadores, un vehículo acuoso y un conjugado que comprende un ligando de direccionamiento y una unión radioisotópica a un agente quelante de metales. El ligando de direccionamiento puede ser un compuesto de molécula pequeña o un péptido tal como un péptido monocíclico. El ligando de direccionamiento puede configurarse para unirse a un objetivo tumoral. El agente estabilizador puede comprender un estabilizador por radiólisis, un agente quelante de metales libre y/o un estabilizador de pH. En el presente documento, se proporcionan también métodos para preparar las composiciones radiofarmacéuticas y métodos para tratar el cáncer mediante la administración de las composiciones radiofarmacéuticas descritas.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163228535P | 2021-08-02 | 2021-08-02 | |
| US17/665,202 US11541134B1 (en) | 2021-08-02 | 2022-02-04 | Stabilized compositions of radionuclides and uses thereof |
| US202263329306P | 2022-04-08 | 2022-04-08 | |
| PCT/US2022/039088 WO2023191839A2 (en) | 2021-08-02 | 2022-08-01 | Stabilized compositions of radionuclides and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024001826A2 true CO2024001826A2 (es) | 2024-03-07 |
Family
ID=87803949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0001826A CO2024001826A2 (es) | 2021-08-02 | 2024-02-21 | Composiciones estabilizadas de radionucleidos y sus usos |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4380633A2 (es) |
| JP (1) | JP2024530000A (es) |
| KR (1) | KR20240053674A (es) |
| AU (1) | AU2022449868A1 (es) |
| CA (1) | CA3227042A1 (es) |
| CL (1) | CL2024000290A1 (es) |
| CO (1) | CO2024001826A2 (es) |
| IL (1) | IL310530A (es) |
| MX (1) | MX2024001620A (es) |
| PE (1) | PE20240917A1 (es) |
| TW (1) | TW202320865A (es) |
| WO (1) | WO2023191839A2 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022449868A1 (en) * | 2021-08-02 | 2024-02-15 | Rayzebio, Inc. | Stabilized compositions of radionuclides and uses thereof |
| CN118022013B (zh) * | 2024-04-11 | 2024-07-19 | 成都中核高通同位素股份有限公司 | 一种放射性标记的偶联物的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022513256A (ja) * | 2018-12-18 | 2022-02-07 | プロビンシャル・ヘルス・サービシーズ・オーソリティ | デュアルモード１８ｆ標識セラノスティック化合物及びその使用 |
| MX2021013667A (es) * | 2019-05-10 | 2022-01-31 | Janssen Biotech Inc | Quelantes macrocíclicos y métodos de uso de estos. |
| AU2022449868A1 (en) * | 2021-08-02 | 2024-02-15 | Rayzebio, Inc. | Stabilized compositions of radionuclides and uses thereof |
-
2022
- 2022-08-01 AU AU2022449868A patent/AU2022449868A1/en active Pending
- 2022-08-01 PE PE2024000177A patent/PE20240917A1/es unknown
- 2022-08-01 EP EP22936006.0A patent/EP4380633A2/en active Pending
- 2022-08-01 TW TW111128839A patent/TW202320865A/zh unknown
- 2022-08-01 JP JP2024506472A patent/JP2024530000A/ja active Pending
- 2022-08-01 WO PCT/US2022/039088 patent/WO2023191839A2/en active Application Filing
- 2022-08-01 IL IL310530A patent/IL310530A/en unknown
- 2022-08-01 MX MX2024001620A patent/MX2024001620A/es unknown
- 2022-08-01 KR KR1020247006415A patent/KR20240053674A/ko unknown
- 2022-08-01 CA CA3227042A patent/CA3227042A1/en active Pending
-
2024
- 2024-01-31 CL CL2024000290A patent/CL2024000290A1/es unknown
- 2024-02-21 CO CONC2024/0001826A patent/CO2024001826A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240053674A (ko) | 2024-04-24 |
| WO2023191839A9 (en) | 2023-11-09 |
| WO2023191839A3 (en) | 2024-01-04 |
| CA3227042A1 (en) | 2023-10-05 |
| JP2024530000A (ja) | 2024-08-14 |
| PE20240917A1 (es) | 2024-04-30 |
| MX2024001620A (es) | 2024-02-28 |
| TW202320865A (zh) | 2023-06-01 |
| IL310530A (en) | 2024-03-01 |
| EP4380633A2 (en) | 2024-06-12 |
| WO2023191839A2 (en) | 2023-10-05 |
| AU2022449868A1 (en) | 2024-02-15 |
| CL2024000290A1 (es) | 2024-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024001826A2 (es) | Composiciones estabilizadas de radionucleidos y sus usos | |
| CL2023000847A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| CO2017011536A2 (es) | Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo | |
| CL2018003550A1 (es) | Complejos radio-farmacéuticos. | |
| PH12020550898A1 (en) | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide | |
| PE20170140A1 (es) | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer | |
| UY35147A (es) | Anticuerpos anti-ceacam5 y usos de éstos. | |
| HRP20190628T1 (hr) | Sredstva za liječenje tumora, njihova uporaba i postupak iste | |
| MX2017003886A (es) | Conjugado radiofarmaceutico de un metabolito y un agente epr para tratar celulas tumorales. | |
| ECSP17038089A (es) | Complejos radiofarmacéuticos | |
| EA201890894A1 (ru) | Комбинированная терапия | |
| CL2023000289A1 (es) | Combinaciones para el tratamiento de cáncer | |
| BR112016029024A8 (pt) | composto, composição farmacêutica e uso | |
| BR112023026747A2 (pt) | Métodos e composições para direcionamento de pd-l1 | |
| BR112022000297A2 (pt) | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos | |
| CL2023002966A1 (es) | Compuestos de oxoisoindolina sustituidos con piridinilo | |
| WO2019147338A3 (en) | Radiopharmaceuticals and methods of use thereof | |
| CO2018010024A2 (es) | Complejos radiofarmacéuticos | |
| AR126667A1 (es) | Composiciones de radioisótopos estabilizadas y sus usos | |
| CL2021003525A1 (es) | Ligandos de antígeno de membrana específico de próstata (psma) y sus usos | |
| AR121643A1 (es) | Radioinmunoconjugados dirigidos a fgfr3 y usos de estos | |
| BR112022022590A2 (pt) | Formulações farmacêuticas de acetato de abiraterona e niraparibe | |
| EA202092270A1 (ru) | Применение конъюгатов антитело-лекарственное средство, содержащих агенты, разрушающие тубулин, для лечения солидной опухоли | |
| AR111637A1 (es) | Composiciones dirigidas | |
| Leyva Ramos et al. | Bifunctional chelating agents used in the synthesis of radiopharmaceuticals |